Stryker Co. (NYSE:SYK) Shares Sold by Moser Wealth Advisors LLC

Moser Wealth Advisors LLC cut its position in Stryker Co. (NYSE:SYK) by 4.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,495 shares of the medical technology company’s stock after selling 349 shares during the quarter. Stryker accounts for 1.4% of Moser Wealth Advisors LLC’s portfolio, making the stock its 18th largest position. Moser Wealth Advisors LLC’s holdings in Stryker were worth $2,244,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Bremer Bank National Association lifted its position in shares of Stryker by 4.0% during the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock worth $266,000 after purchasing an additional 34 shares during the last quarter. Simon Quick Advisors LLC lifted its position in shares of Stryker by 3.0% in the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock worth $347,000 after buying an additional 34 shares during the last quarter. Consolidated Portfolio Review Corp boosted its holdings in shares of Stryker by 3.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after buying an additional 34 shares during the period. FourThought Financial Partners LLC grew its position in shares of Stryker by 3.3% during the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after buying an additional 34 shares during the last quarter. Finally, MBL Wealth LLC raised its position in shares of Stryker by 4.6% during the 4th quarter. MBL Wealth LLC now owns 850 shares of the medical technology company’s stock worth $255,000 after purchasing an additional 37 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SYK. Barclays increased their target price on Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and lifted their price objective for the company from $315.00 to $360.00 in a research note on Wednesday, January 31st. Robert W. Baird increased their target price on shares of Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Wednesday, May 1st. Finally, Wells Fargo & Company lifted their price target on Stryker from $364.00 to $381.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.94.

Stryker Stock Performance

SYK traded up $1.30 during midday trading on Thursday, reaching $330.58. The company’s stock had a trading volume of 170,754 shares, compared to its average volume of 1,317,533. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. The company has a fifty day simple moving average of $346.05 and a 200 day simple moving average of $318.84. The stock has a market cap of $125.93 billion, a P/E ratio of 37.59, a PEG ratio of 2.54 and a beta of 0.91. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. During the same quarter in the previous year, the firm posted $2.14 earnings per share. Stryker’s revenue was up 9.7% compared to the same quarter last year. Research analysts expect that Stryker Co. will post 11.94 earnings per share for the current year.

Insider Activity

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.